Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of Cetirizine Chewable Tablets
NCT03772158Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cetirizine in allergy (5 arms), sponsored by Johnson & Johnson. Primary endpoints: Maximum Observed Plasma Concentration at 32 hours and Area Under the Plasma Concentration-Time Curve to Last Measurable Concentration at 32 hours. Started Dec 2018; status: completed.
02
Drugs
cetirizine
03
Conditions
allergy
Beyond the preview
Go deeper on NCT03772158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772158.